Cargando…
Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
BACKGROUND: Acute leukemias represent deadly malignancies that require better treatment. As a challenge, treatment is counteracted by a microenvironment protecting dormant leukemia stem cells. METHODS: To identify responsible surface proteins, we performed deep proteome profiling on minute numbers o...
Autores principales: | Bahrami, Ehsan, Schmid, Jan Philipp, Jurinovic, Vindi, Becker, Martin, Wirth, Anna-Katharina, Ludwig, Romina, Kreissig, Sophie, Duque Angel, Tania Vanessa, Amend, Diana, Hunt, Katharina, Öllinger, Rupert, Rad, Roland, Frenz, Joris Maximilian, Solovey, Maria, Ziemann, Frank, Mann, Matthias, Vick, Binje, Wichmann, Christian, Herold, Tobias, Jayavelu, Ashok Kumar, Jeremias, Irmela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329331/ https://www.ncbi.nlm.nih.gov/pubmed/37422628 http://dx.doi.org/10.1186/s12943-023-01803-0 |
Ejemplares similares
-
Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients
por: Zeller, Christina, et al.
Publicado: (2022) -
In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
por: Wirth, Anna-Katharina, et al.
Publicado: (2022) -
Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL
por: Liu, Wen-Hsin, et al.
Publicado: (2020) -
A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape
por: Kellner, Markus, et al.
Publicado: (2022) -
Anti-leukemic effects of the V-ATPase inhibitor Archazolid A
por: Zhang, Siwei, et al.
Publicado: (2015)